Bioxcel Therapeutics, Inc. Announces Resignation of Reina Benabou as Senior Vice President and Chief Development Officer, Effective July 30, 2021
July 23, 2021 at 09:46 pm
Share
On July 19, 2021, Reina Benabou, M.D., Ph.D., Senior Vice President and Chief Development Officer of BioXcel Therapeutics, Inc. (the “Company”), and a named executive officer in the Company’s proxy statement filed April 27, 2021, tendered her resignation notice to the Company, effective July 30, 2021.
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Companyâs most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
BIOXCEL THERAPEUTICS, INC. 
